Projects

RNDr. Miriam Zaťovičová, CSc.

National

Current
  • Characterization of the soluble form of carbonic anhydrase IX in molecular subtypes of breast cancer and its significance for prognosis.
    Program: VEGA
    Duration: 1. 1. 2024 – 31. 12. 2027
  • Regulation of hypoxic signalling in renal carcinoma with focus on the role of carbonic anhydrase IX in the tumor microenvironment
    Program: VEGA
    Duration: 1. 1. 2024 – 31. 12. 2027
Finished
  • Cell-in-cell phenomena as microevolutionary processes in cancer progression: a role for hypoxia-induced carbonic anhydrase IX
    Program: SRDA
    Duration: 1. 7. 2020 – 30. 6. 2024
  • Carbonic anhydrase IX: one of the key components of exosomes secreted from cancer cells
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2023
  • Clinical evaluation of prognostic and predictive value of tissue and serum Carbonic Anhydrase IX in breast cancer
    Program: Other projects
    Duration: 1. 11. 2019 – 31. 12. 2022
  • Immune response to SARS-CoV-2 infection and development of clinically relevant virological tests to improve the management of the COVID-19 pandemic
    Program: SRDA
    Duration: 16. 9. 2020 – 31. 12. 2021
  • Activity Assay of Transfer Factor, Immunostimulatory Drug from Leukocytes Extract And Its Preparation Standardization
    Program: SRDA
    Duration: 1. 7. 2016 – 31. 12. 2020
  • Drug repurposing as a novel approach to therapy of colorectal carcinoma: molecular mechanisms and potential applications
    Program: VEGA
    Duration: 1. 1. 2016 – 31. 12. 2019
  • Soluble and/or exosome-associated Carbonic anhydrase IX as a biologically active molecule.
    Program: VEGA
    Duration: 1. 1. 2016 – 31. 12. 2019
  • Graphene - based nanoplatform for detection of cancer
    Program: SRDA
    Duration: 1. 7. 2015 – 30. 6. 2019
  • Carbonic anhydrase IX as a functional component of cancer progression: the role in epithelial-mesenchymal transition and intercellular signaling
    Program: SRDA
    Duration: 1. 7. 2012 – 31. 12. 2015
  • Regulation of carbonic anhydrase IX release and biological role of shed ectodomain in tumor cell-cell interactions
    Program: VEGA
    Duration: 1. 1. 2012 – 31. 12. 2015
  • Study of molecular mechanisms of carbonic anhydrase IX regulation and significance of its expression in colorectal cancer.
    Program: VEGA
    Duration: 1. 1. 2012 – 31. 12. 2015
  • Center of excellence for the study of metabolic aspects of development, diagnostics and treatment of cancer diseases
    Program:
    Duration: 1. 7. 2011 – 31. 12. 2014
  • Redirected immunotherapy: a novel therapeutic concept for treatment of viral and cancer dieases
    Program: VEGA
    Duration: 1. 1. 2010 – 31. 12. 2012
  • Centre of Excellence for Translational Research in Molecular medicine
    Program: EU Structural Funds Research & Development
    Duration: 1. 6. 2010 – 31. 5. 2012
  • Biological properties and immunotherapeutic potential of the monoclonal antibodies specific for the tumor-associated protein CA IX
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • Significance of the carbonic anhydrase IX as a non-invasive prognostic indicator and a molecular target in renal cell carcinoma
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • Significance of the carbonic anhydrase IX as a non-invasive prognostic indicator and a molecular target in renal cell carcinoma
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • Extracelular form of hypoxia - induced tumor - associated carbonic adhydrase IX /CA IX/: molecular mechanisms of shedding and biological significance in oncogenesis
    Program: VEGA
    Duration: 1. 1. 2006 – 31. 12. 2008
  • Interplay between lymphocytic choriomeningitis virus and cellular proteins during the persistent infection
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
  • -
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
Employees